RNA

RNA research
#Regenerative Medicine #RNA #Small RNA #The University of Manchester #Wound care

Small RNAs promote wound-healing without scarring

A class of molecules playing a crucial role in the regulation of gene expression and other cellular processes can restore normal skin structure rather than producing a scar, a University of Manchester-led study suggests. The new findings show that microRNA-29s, a class of small RNAs, could… Read More

#Editor's Choice #News

Oligonucleotide
#Alpha-1 antitrypsin deficiency #Biopharmaceuticals #Genetic medicines #Korro Bio #Oligonucleotides #RNA

RNA editing oligonucleotide selected for AATD treatment 

Korro Bio, a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, has nominated its first development candidate, KRRO-110, for the potential treatment of alpha-1 antitrypsin deficiency (AATD).   KRRO-110 is an RNA editing oligonucleotide delivered to liver cells… Read More

#News

Human heart
#Cardiovascular disease #Ethris #Heart attack #Heart failure #Heqet Therapeutics #Partnership #RNA

Partners hope to regenerate heart tissue using ncRNA

Ethris and Heqet Therapeutics have revealed plans to collaborate on RNA-based therapeutics for heart attack and heart failure, using non coding RNAs (ncRNAs) in regenerating heart tissue. Under the terms of the agreement, Heqet Therapeutics will lead the development of the programme, while Ethris will provide… Read More

#Business & Investment #News

#Collaboration #Ginkgo Bioworks #Pfizer #RNA

Pfizer does $331 million deal with Ginkgo Bioworks

Ginkgo Bioworks has announced a collaboration with Pfizer focused on the discovery of RNA-based drug candidates.   In the collaboration, Pfizer will leverage Ginkgo’s proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas. Ginkgo will receive an upfront payment and… Read More

#Business & Investment #News

RNA strand
#Covid-19 #RNA #RNA sequencing #Roundtable

Register now to join our roundtable on the delivery of RNA therapeutics

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ will be free to attend on 27 September at 7am PST | 10am ET | 3PM BST | 4PM CET. Join this… Read More

Webinar date:
Sponsored by Azenta Life Sciences
#News

siRNA
#Bone disease #Preclinical investigations #RNA #siRNA #SiSaf

Positive preclinical data for siRNA therapy for osteopetrosis

RNA therapeutics company SiSaf has published positive safety and efficacy data for its siRNA therapy for Autosomal Dominant Osteopetrosis 2 (ADO2). The data demonstrate that siRNA complexed with SiSaf’s silicon stabilised hybrid lipid nanoparticles (sshLNP) was able to significantly downregulate expression of an ADO2-specific mutant gene. Read More

#News

RNA
#Covid-19 #RNA #RNA sequencing #Roundtable

Roundtable: Panellists discuss the future RNA pipeline

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ will be free to attend on 27 September at 7am PST | 10am ET | 3PM BST | 4PM CET. Join this… Read More

Webinar date:
Sponsored by Azenta Life Sciences
#News

microRNA
#Covid-19 #RNA #RNA sequencing #Roundtable

Roundtable: Discover how Covid-19 has influenced RNA research

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ will be free to attend on 27 September at 7am PST | 10am ET | 3PM BST | 4PM CET. Join this… Read More

Webinar date:
Sponsored by Azenta Life Sciences
#News

RNA
#Covid-19 #RNA #RNA sequencing #Roundtable

What are the challenges in the delivery of RNA therapeutics?

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ will be free to attend on 27 September at 7am PST | 10am ET | 3PM BST | 4PM CET. Join this… Read More

Webinar date:
Sponsored by Azenta Life Sciences
#News

RNA
#Covid-19 #RNA #RNA sequencing #Roundtable

Exclusive roundtable on the delivery of RNA therapeutics

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ will be free to attend on 27 September at 7am PST | 10am ET | 3PM BST | 4PM CET. Join this… Read More

Webinar date:
Sponsored by Azenta Life Sciences
#News

RNA
#Covid-19 #RNA #RNA sequencing #Roundtable

What are some of the biggest challenges related to the development & delivery of RNA therapeutics?

In this roundtable, moderated by DDW and sponsored by Azenta Life Sciences, learn about the biggest challenges related to the delivery of RNA therapeutics. Roundtable panellists include Dr Philip Cruz, UK Medical Director, Moderna, Dr Neill Liptrott, Reader in Pharmacology and Immuno-compatability, University of Liverpool, and Reece Armstrong, Editor, DDW. Read More

Webinar date:
Sponsored by Azenta Life Sciences
#Webinars

RNA
#Laboratoires Théa #Mergers and acquisitions #Ophthalmology #ProQR Therapeutics #RNA

Théa acquires ProQR’s RNA ophthalmic assets

ProQR Therapeutics and Laboratoires Théa have announced an agreement in which ProQR will divest its late-stage ophthalmic assets, sepofarsen and ultevursen, to Théa. Under the terms of the agreement, ProQR will receive an initial payment of €12.5M and will also be eligible for up to €135M… Read More

#Business & Investment #News

Patient using blood pressure monitor
#Alnylam Pharmaceuticals #blood #Cardiovascular disease #Hypertension #Phase I trial #RNA

Positive Phase I results for RNAi therapeutic in hypertension

Alnylam Pharmaceuticals has revealed results from its Phase I study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension. The results are published in the New England Journal of Medicine (NEJM). The key data showed that… Read More

#News

RNA strand
#Evotec #Funding #Immunology / Virology & Vaccines #Pandemic prevention #RNA #RNA sequencing

Grant supports discovery of RNA-targeting Henipavirus therapeutics

Evotec has received a $1.7 million grant from Open Philanthropy, a philanthropic funder prioritising global health and wellbeing. Under the grant, Evotec aims to discover and develop RNA-targeting small molecules as potential first-in-class therapeutics against Henipaviruses. Henipavirus is a genus of zoonotic viruses that… Read More

#News

#Oncology #RNA #Solid tumours

New solid tumour panel could save time and expense 

Integrated DNA Technologies (IDT) has launched a new solution to optimise operational efficiency and the identification of solid cancer tumours.   The IDT Archer FUSIONPlex Core Solid Tumor Panel is a first-line cancer research testing solution that has been expanded and optimised for additional single nucleotide variant (SNV)… Read More

#News